Meeting
2015 ASCO Annual Meeting
Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance).
Authors
Nadia N. Laack
Mayo Clinic, Rochester, MN
Nadia N. Laack , Evanthia Galanis , S. Keith Anderson , Clinton Leinweber , Jan C. Buckner , Caterina Giannini , Francois J. Geoffroy , Derek Richard Johnson , Glenn Jay Lesser , Kurt A. Jaeckle , Jann Nagina Sarkaria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00869401
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2013)
DOI
10.1200/jco.2015.33.15_suppl.2013
Abstract #
2013
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study.
First Author: Nadia N. Laack
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2014 ASCO Annual Meeting
Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma.
First Author: Abdullah Khalaf Altwairgi
Poster
2013 ASCO Annual Meeting
Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.
First Author: Martin Kelly Nicholas